Large Study Links GLP-1s to Lower Risk of Multiple Cancers

— Patients taking the drugs for obesity had a 41% lower risk of related cancers

June 8, 2026

• 3 min read

Patients taking GLP-1 receptor agonists for weight loss had a 41% lower risk of obesity-associated cancers compared with patients prescribed diet or exercise.Patients taking tirzepatide had substantially greater cancer risk reduction versus those taking semaglutide.The results add to those of multiple recent studies showing a reduced risk of cancer in association with GLP-1 treatment.

Patients taking GLP-1 receptor agonists for obesity had a 41% lower risk of obesity-related cancers as compared with patients treated with diet or exercise, a large propensity-matched cohort study showed.